{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:28:41Z","timestamp":1793046521900,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:45Z","timestamp":1749770145000},"page":"374-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elective Regional Nodal Irradiation in Prostate Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Srinivas","family":"Chilukuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Dal","family":"Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semradonc.2025.04.010_bib0001","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1470-2045(21)00242-4","article-title":"Elective nodal radiotherapy in prostate cancer","volume":"22","author":"De Meerleer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.010_bib0002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clgc.2013.04.031","article-title":"A better understanding of lymphatic drainage of the prostate with modern imaging and surgical techniques","volume":"11","author":"Swanson","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0003","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","article-title":"The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study","volume":"53","author":"Mattei","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.010_bib0004","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2012.06.057","article-title":"Mapping of pelvic lymph node metastases in prostate cancer","volume":"63","author":"Joniau","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - An updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0006","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/rg.2019180079","article-title":"Revisiting prostate cancer recurrence with PSMA PET: Atlas of typical and Atypical patterns of spread","volume":"39","author":"Barbosa","year":"2019","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0008","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2008.07.053","article-title":"Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era","volume":"74","author":"Nguyen","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.010_bib0009","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers15061683","volume":"15","author":"Di Pierro","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.semradonc.2025.04.010_bib0010","article-title":"External validation of nomograms for the identification of pelvic nodal dissection candidates among prostate cancer patients with negative preoperative prostate-specific membrane antigen positron emission tomography","volume":"S2588-9311","author":"Gandaglia","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.010_bib0011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euo.2023.03.010","volume":"6","author":"Vis","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.010_bib0012","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.euo.2018.11.002","article-title":"Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer","volume":"2","author":"Xu","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.010_bib0013","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.010_bib0014","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.010_bib0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk Prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.semradonc.2025.04.010_bib0016","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.23.02394","article-title":"Elective pelvic lymph node radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A postrandomization analysis","volume":"42","author":"Sayan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.010_bib0017","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0018","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.010_bib0019","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.010_bib0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0021","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.prro.2023.08.006","article-title":"Long-term outcomes following fairly brief androgen suppression and stereotactic radiation therapy in high-risk prostate cancer: Update from the FASTR\/FASTR-2 trials","volume":"14","author":"Tang","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.010_bib0022","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A phase I\/II trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (FASTR-2): Preliminary results and toxicity analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0023","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation","volume":"104","author":"Alayed","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.010_bib0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT Trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open;"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2019.03.022","article-title":"Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for Gleason grade group 5 Prostate cancer: A retrospective analysis","volume":"77","author":"Sandler","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0028","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0029","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.ijrobp.2017.07.041","article-title":"Phase 1\/2 dose-escalation study of the use of intensity modulated radiation therapy to treat the prostate and pelvic nodes in patients with prostate cancer","volume":"99","author":"Reis Ferreira","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.semradonc.2025.04.010_bib0030","first-page":"03773","article-title":"Pelvic regional control with 25 gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: Pooled prospective outcomes from the SHARP Consortium","volume":"S0360-3016","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.07.018","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.010_bib0032","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late adverse effects of prostate-only or pelvic stereotactic radiation therapy in prostate cancer: A comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2023.07.020","article-title":"Consensus delineation guidelines for pelvic lymph node Radiation Therapy of prostate cancer: on behalf of the Francophone Group of Urological Radiation Therapy (GFRU)","volume":"118","author":"De Hertogh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.010_bib0035","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy","volume":"92","author":"Harris","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.010_bib0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clon.2024.04.001","article-title":"Patterns of failure after prostate-only radiotherapy in high-risk prostate cancer: Implications for refining pelvic nodal contouring guidelines","volume":"36","author":"Singh","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0037","first-page":"130","article-title":"PEARLS - A multicentre phase II\/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and\/or para-aortic lymph nodes at presentation","volume":"37","author":"Murray","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0038","article-title":"Acute enteritis with pelvic SBRT: influence of bowel delineation methods","volume":"52","author":"Dinesan","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0039","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.010_bib0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2024.03.023","article-title":"Late urinary toxicity and quality of life with pelvic radiation therapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase 3 trial","volume":"120","author":"Maitre","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.010_bib0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14338\/IJPT-21-00042.1","article-title":"Comparison of estimated late toxicities between IMPT and IMRT based on multivariable NTCP models for high-risk prostate cancers treated with pelvic nodal radiation","volume":"9","author":"Chilukuri","year":"2022","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110041","article-title":"Modeling frameworks for radiation induced lymphopenia: A critical review","volume":"190","author":"Cella","year":"2024","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.010_bib0043","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2024.09.043","article-title":"Setting the stage: feasibility and baseline characteristics in the PARTIQoL trial comparing proton therapy versus Intensity modulated radiation therapy for localized prostate cancer","volume":"121","author":"Wisdom","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.010_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00031.1","article-title":"Genitourinary subcommittee of the particle therapy co-operative group. Consensus statement on proton therapy for prostate cancer","volume":"8","author":"Bryant","year":"2021","journal-title":"Int J Part Ther"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2022.11.027","article-title":"Late toxicity of moderately hypofractionated intensity-modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer","volume":"115","author":"Choo","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.010_bib0046","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijrobp.2016.11.014","article-title":"Patterns of recurrence after postprostatectomy fossa radiation therapy identified by C-11 choline positron emission tomography\/computed tomography","volume":"97","author":"Parker","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.010_bib0047","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis","volume":"59","author":"Briganti","year":"2011","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.010_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.semradonc.2025.04.010_bib0049","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.semradonc.2025.04.010_bib0050","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.010_bib0051","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.euf.2022.09.005","article-title":"Evaluating the impact of prostate only versus Pelvic radiotherapy for pathological node-positive prostate cancer: First results from the Multicenter phase 3 PROPER trial","volume":"9","author":"Fonteyne","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"10338","key":"10.1016\/j.semradonc.2025.04.010_bib0052","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): An international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.04.010_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109339","article-title":"Integrating PET\/CT, radiomics and clinical data: an advanced multi-modal approach for lymph node metastasis prediction in prostate cancer","volume":"184","author":"\u00d6\u011f\u00fclm\u00fc\u015f","year":"2025","journal-title":"Comput Biol Med"},{"issue":"5_suppl","key":"10.1016\/j.semradonc.2025.04.010_bib0054","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.399","article-title":"Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial","volume":"43","author":"Pollack","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:06:01Z","timestamp":1750791961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000384"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.010","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elective Regional Nodal Irradiation in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}